AVOIDANCE AND MANAGEMENT OF ADVERSE REACTIONS TO ANTITUBERCULOSIS DRUGS

被引:29
作者
PATEL, AM
MCKEON, J
机构
[1] Queensland Health Chest Clinic, Brisbane, Queensland, 4002, PO Box 232, North Quay
关键词
D O I
10.2165/00002018-199512010-00001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Potent antibiotics are required to cure tuberculosis and reduce the burden of illness in the community. Minor adverse-effects are commonly encountered and can be managed by reassurance and explanation. Significant hypersensitivity reactions require cessation of all antituberculosis drugs. Adverse effects should be treated appropriately. An effective antituberculosis regimen should be re-established as soon as possible. Desensitisation may be necessary if suitable alternative drugs cannot be used. In the event of drug-induced hepatitis, all hepatotoxic drugs should be ceased until symptoms resolve and liver function tests return to normal. Other significant direct toxic effects should be promptly detected and appropriately treated. A thorough knowledge of potential adverse reactions and pharmacokinetics is essential for any physician using antituberculosis drugs.
引用
收藏
页码:1 / 25
页数:25
相关论文
共 160 条
[1]  
Kochi A., The global tuberculosis situation and the new control strategy of the World Health Organisation, Tubercle, 72, pp. 1-6, (1991)
[2]  
Fox W., Tuberculosis in India, past, present and future, Indian J Tuberculosis, 37, (1990)
[3]  
Girling D.J., Adverse effects of antituberculosis drugs, Drugs, 23, pp. 56-74, (1982)
[4]  
Pannier R., Drug induced lung disease, Eur J Respir Dis, 64, 126, (1983)
[5]  
Antituberculosis regimens of chemotherapy. Recommendation from the committee on treatment of IUALTD, Bull Int Union Tuberc Lung Dis, 63, 2, pp. 60-64, (1988)
[6]  
Wong C.T., Saha N., Changes in serum proteins (albumin, immunoglobulins and acute phase proteins) in pulmonary tuberculosis during therapy, Tubercle, 71, (1990)
[7]  
Hawkins J.E., Drug susceptibility testing, The mycobacteria. A sourcebook. Part A, (1984)
[8]  
Fox W., Drug combinations and the bioavailability of rifampicin, Tubercle, 71, (1990)
[9]  
Acocella G., Human bioavailability studies, Bull Int Union Tuberc Lung Dis, 64, pp. 38-40, (1989)
[10]  
TM, Avery’s drug treatment: principles and practice of clinical pharmacology and therapeutics, (1987)